

Curriculum Vitae

Prof. Saverio Francesco Retta

PERSONAL DATA

- Date of Birth:** 05 December 1963
- Place of Birth:** Reggio Calabria (RC), Italy
- Military Service:** served as Sergeant of the Marina Militare Italiana from 30/09/1984 to 31/03/1986
- Marital status:** married, with three children
- Current Position:** Full Professor of Applied Biology at the Department of Clinical and Biological Sciences, School of Medicine and Surgery, University of Torino (TO), Italy. <https://www.dscb.unito.it/persona/saverio.retta>

EDUCATION AND PROFESSIONAL QUALIFICATIONS

- 1988 Laurea Degree in Biological Sciences at the University of Messina (ME), Italy; summa cum laude (110/110 e lode)
- 1988-89 Postgraduate Specialization Course with residential Master's Programs in Marine Biology, Aquaculture, Informatics and Communication Sciences. University of Messina (ME), ITEA (Rome), National Research Council (CNR) of Lesina (FG)
- 1990 Professional Qualification to practice as Biologist
- 1990-91 Research fellow of the National Research Council (CNR) at the "CNR Institute of Genetic Improvement of Orto and Flower Plants", Portici (NA).
- 1992-94 Research fellow at the Fidia Pharmaceuticals S.p.A., Abano Terme (PD), for a scientific and managerial training program for the formation of "Research Project Leaders"
- 1995-96 Research fellow of the National Research Council (CNR) at the Department of Genetic, Biology and Biochemistry, School of Medicine and Surgery, University of Torino (TO)
- 1997 Postgraduate Specialization Degree in Biotechnological Applications at the University of Torino (TO), Italy; summa cum laude (70/70 e lode)
- 2014 National Scientific Qualification (Abilitazione Scientifica Nazionale) for a position of Full Professor of Applied Biology

ACADEMIC POSITIONS

- 1996-1999 - Assistant Professor of Applied Biology at the Department of Biopathology and Biomedical Technologies, School of Medicine and Surgery, University of Palermo (Italy)
- 1999-2002 - Assistant Professor of Applied Biology at the Department of Genetic, Biology and Biochemistry, School of Medicine and Surgery, University of Torino (Italy)
- 2002-2010 - Associate Professor of Applied Biology at the Department of Genetic, Biology and Biochemistry, School of Medicine and Surgery, University of Torino (Italy)
- 2011-2021 - Associate Professor of Applied Biology at the Department of Clinical and Biological Sciences, School of Medicine and Surgery, University of Torino (Italy)
- 2021-present - Full Professor of Applied Biology at the Department of Clinical and Biological Sciences, School of Medicine and Surgery, University of Torino (Italy)

RESEARCH ACTIVITIES IN FOREIGN COUNTRIES

- 1995 Research fellow of Prof. David Critchley at the Department of Biochemistry, University of Leicester, Leicester (U.K.)
- 1997-98 Research fellow of Prof. Keith Burridge at the Department of Cell Biology and Anatomy, University of North Carolina at Chapel Hill, Chapel Hill (NC) (USA)
- 2003 Visitor Scientist in the laboratory of Prof. Victor Small at the Institute of Molecular Biology, Austrian Academy of Sciences, Salzburg (Austria)
- 2004 Visitor Scientist in the laboratory of Prof. Victor Small at the Institute of Molecular Biotechnology (IMBA), Vienna (Austria)

CURRENT PROFESSIONAL MEMBERSHIP

1996-present - Member of the “Associazione Italiana di Biologia e Genetica” (AIBG)

2011-present - Founder and coordinator of the CCM Italia research network (CCM Italia, <https://www.ccmitalia.unito.it>)

2012-present - Founder and honorary president of the Associazione Italiana Angiomi Cavernosi (AIAC, <https://www.aiac.unito.it>)

PAST PROFESSIONAL MEMBERSHIP

- Member of the “Associazione di Biologia Cellulare e del Differenziamento” (ABCD)

- Member of North American Vascular Biology Organization (NAVBO)

- Member of the Society for Free Radical Research Europe (SFRR Europe)

- Member of the Society for Redox Biology and Medicine (SfRBM USA)

EDITORIAL BOARD MEMBERSHIP

- 2018-present - Member of the Editorial Board of **Antioxidants** (ISSN 2076-3921), published by MDPI, Basel, Switzerland.
- 2021-present - Member of the Journal Editorial Board of **Biomedicines** (ISSN 2227-9059), published by MDPI, Basel, Switzerland.
- 2021-present - Member of the Journal Editorial Board of **International Journal of Molecular Sciences** (ISSN 1422-0067), published by MDPI, Basel, Switzerland.
- 2021-present - Member of the Journal Editorial Board of **Vessel Plus** (ISSN 2574-1209), published by OAE Publishing Inc., Alabama, CA 91801, USA.

COORDINATION OR PARTICIPATION TO STEERING COMMITTEE OF RESEARCH NETWORKS

- 2011-present - Founder and coordinator of the Italian multidisciplinary research network **CCM Italia** (<https://www.ccmitalia.unito.it>), which is focused on the genetic disease Cerebral Cavernous Malformation (CCM) and recognized at national and international level.

ORGANIZATION OF INTERNATIONAL SYMPOSIA

- 2018 - Organizer and chairman of the International Symposium “*Crosstalk between oxidative stress and inflammation in cerebrovascular disease: mechanisms and therapeutic intervention*”, which has been held within the framework of the “19th biennial meeting of the Society for Free Radical Research International (SFRRRI)”, June 4-7, 2018, Lisbon Conference Centre, Lisbon, Portugal ([SFRRRI Lisboa 2018](#)) (Symposium date: June 5, 2018) (<https://sfrrri2018lisbon.org/ideia.pt/en/>).
- 2019 - Organizer and chairman of the International Symposium “*Oxy-Inflammation, Redox Signaling and Autophagy: Crosstalk in Health and Disease*”, which has been held as plenary session within the framework of the “26th Annual Conference of the Society for Redox Biology and Medicine (SfRBM 2019)”, November 20-23, 2019, Las Vegas, NV, USA (Plenary session date: November 21, 2019) (<https://sfrbm.org/meetings/2019-annual-conference/>).

PAST RESEARCH INTERESTS

Professor Retta's research activities have spanned the last 30 years. Initially, the research interests have been mainly focused on the study of the molecular mechanisms underlying the function of integrins and cadherins in distinct cellular processes, including adhesion, migration and proliferation. In particular, the major research topics have been the analysis of signal transduction pathways triggered by integrin receptors of the beta1 and alphaV families, as well as the study of the molecular mechanisms underlying the crosstalk between adhesion receptors, including integrins and cadherins, the dynamics of the actin cytoskeleton, and the functional roles of integrin-regulatory proteins, including ICAP1, RAP1 and KRIT1. Among the most recent accomplishments related to these topics there are the characterization of distinct ICAP1 functions (Degani et al., 2002; Bouvard et al., 2003; Fournier et al., 2005), the discovery of a novel isoform of KRIT1 (Retta et al., 2004), the finding that RAP1 mediates the crosstalk between cadherins and integrins (Balzac et al., 2005; Retta et al., 2006), the characterization of structural and functional differences between KRIT1A and KRIT1B isoforms (Francalanci et al., 2009), the identification of a unique interplay between RAP1 and E-cadherin regulating self-renewal of human embryonic stem cells (Li et al., 2010), the identification and characterization of a novel role for KRIT1 in the molecular machinery that controls the homeostasis of intracellular Reactive Oxygen Species (ROS) to prevent oxidative cellular damage (Goitre et al., 2010; Goitre et al., 2012), the characterization of the antioxidant effectiveness of a novel, recombinant phenolic compound (yeast avenanthramide) in cellular models (Moglia et al. 2010), the identification and characterization of mutations in the three known CCM genes (*CCM1*, *CCM2* and *CCM3*) in a cohort of Italian patients with Cerebral Cavernous Malformation (D'Angelo et al., 2011), the definition of clinical implications of genetic and molecular bases of CCM disease (Bacigaluppi et al., 2012), and the identification of a novel KRIT1 interactor involved in the control of actin cytoskeleton dynamics and cell resistance to oxidative stress (Guazzi et al., 2012).

CURRENT RESEARCH INTERESTS

Current research focuses on the characterization of molecular and cellular mechanisms underlying the pathogenesis of Cerebral Cavernous Malformations (CCM), a major cerebrovascular disease of proven genetic origin characterized by abnormally dilated and leaky brain capillaries, and predisposing to seizures, focal neurological deficits, and intracerebral hemorrhage.

Among the recent accomplishments related to this research topic there are the findings that CCM proteins, including KRIT1 (CCM1), CCM2 and CCM3, play important roles in regulating the homeostasis of intracellular reactive oxygen species (ROS) and protecting cells against oxidative stress events, suggesting novel mechanisms for CCM pathogenesis and opening new perspectives for CCM disease prevention and treatment ([Goitre et al., 2010](#); [Goitre et al., 2012](#); [Bacigaluppi et al., 2013](#); [Maddaluno et al., 2013](#); [Goitre et al., 2014](#); [Gibson et al., 2015](#); [Moglia et al., 2015](#); [Trapani and Retta, 2015](#); [Marchi et al., 2015](#); [Choquet et al., 2016](#); [Marchi et al., 2016a](#); [Marchi et al., 2016b](#); [Moglianetti et al., 2016](#); [Retta & Glading 2016](#); [Gotre et al., 2017](#); [Antognelli et al., 2018a](#); [Antognelli et al., 2018b](#); [Perrelli et al., 2018](#); [De Luca et al., 2018](#); [Cianfruglia et al., 2019](#); [Vieceli Dalla Sega et al., 2019](#); [Antognelli et al., 2020](#); [Kim et al., 2020](#); [Retta et al., 2020](#); [De Luca et al., 2021](#); [Perrelli et al., 2021](#); [Perrelli and Retta 2021](#); [Benedetti et al., 2022](#); [Mastrocola et al., 2022](#); [Bianconi et al., 2022](#); [Perrelli et al., 2023a](#); [Perrelli et al., 2023b](#); [Kar et al., 2023](#)).

In this context, Prof. Retta has organized and coordinates an Italian multidisciplinary research network focused on the CCM disease (CCM Italia, <https://www.ccmitalia.unito.it/>), which is aimed at sharing knowledge, expertise and resources among clinical and basic research groups for facilitating breakthroughs into CCM pathogenesis mechanisms and their translational implementation. In particular, this network comprises clinical and research centers located in distinct Italian regions, and involves clinicians and researchers with complementary expertise and interests related to distinct aspects of the CCM disease, including neurosurgeons, neurologists, neuroradiologists, pathological anatomists, geneticists, and cellular and molecular biologists.

Moreover, he has founded a nonprofit patient-researcher organization (AIAC, Associazione Italiana Angiomi Cavernosi, <https://www.aiac.unito.it/>), which is acting on a national scale as an informative and supportive platform to CCM patients, yet interacting with CCM-focused organizations active worldwide, including Angioma Alliance USA, Angioma Alliance Canada and Cavernoma Alliance UK.

RESEARCH WEBLINKs

<http://www.dscb.unito.it/do/gruppi.pl/Show? id=8dgp>

<https://www.ccmitalia.unito.it/>

RESEARCH GRANTS

TELETHON FOUNDATION (project code: GGP15219)

Duration: 01/12/2015 - 01/12/2019.

National Project Coordinator

Partner Units involved: Retta (Torino), Pinton (Ferrara), Trabalzini (Siena)

Project title: Oxidative Stress and Cerebral Cavernous Malformations (CCM): from disease mechanisms toward prevention and treatment.

Total funding: € 430.000

Funding of the Torino research Unit: € 220.000

CRT Foundation (project code: 2017.2318)

Duration: up to 15/06/2021

Project title: "Cerebro-NGS.TO"

Funding: € 30.000

FUTURO IN RICERCA (FUTURE IN RESEARCH) (project code: RBFR106VRR)

Duration: 08/03/2012 – 08/03/2016. Four-year project

Partner Units involved: Moglia (Torino), Retta (Torino)

Project title: Development of a yeast-based system for the production of novel antioxidative phenolic amides with biological properties relevant to human health.

Total funding: € 370.380

PRIN (Progetti di ricerca di Rilevante Interesse Nazionale)

Year 2008 - Two-year project

Project title: Study of the role of KRIT1 in integrin-mediated cell adhesion and in the pathogenesis of cerebral cavernous malformations (CCM1).

Funding of the research unit: € 49,000

TELETHON FOUNDATION

Year 2006 - Three-year project (grant GGP06222)

Project title: Characterization of the cellular functions of Krit1, the disease gene responsible for type 1 Cerebral Cavernous Malformations (CCM1).

Funding: € 241,000

REGIONE PIEMONTE (PIEMONTE REGION)

Year 2006 - Annual project

Finalized Healthcare Research Project 2006 call

Project title: Animal models and genetic screening for the study of the pathogenetic mechanisms of Cerebral Cavernous Malformations.

Funding: € 8.000

CIPE (Comitato Interministeriale per la Programmazione Economica)

Year 2005 - Two-year project

Regione Piemonte 2004 call - Life Sciences Sector

Project title: Characterization of the molecular mechanisms underlying the pathogenesis of cerebral cavernous malformations.

Funding: € 58.000

MINISTERO DEGLI AFFARI ESTERI (MINISTRY OF FOREIGN AFFAIRS)

Year 2004 - Two-year project

Italian-Austrian subcommittee for scientific and technological collaboration

Funding for joint biennial (2004-2005) research and cultural exchange project with the laboratory of prof. Victor Small at the Institute of Molecular Biotechnology (IMBA) of the Academy of Sciences in Vienna (Austria).

Project title: Analysis of KRIT1 functions in integrin-mediated cell adhesion and cerebral cavernous malformations (CCM1) pathogenesis.

Funding: Coverage of living expenses

PRIN (Progetti di ricerca di Rilevante Interesse Nazionale)

Year 2004 - Two-year project

National coordinator of the project

Project title: Study of the role of KRIT1 in integrin-mediated cell adhesion and in the pathogenesis of cerebral cavernous malformations (CCM1).

Total funding: 256.000 Euro

Funding of the research unit: € 87.600

MINISTERO DELLA SANITÀ (MINISTRY OF HEALTH)

Year 2003 - Two-year project

Project title: Analysis of the role of ICAP1 and KRIT1 proteins in cell migration and integrin-mediated angiogenesis.

Funding: € 58.000

PRIN (Progetti di ricerca di Rilevante Interesse Nazionale)

Year 2002 - Two-year project

Project Leader of Silengo research Unit

Project title: Study of the role of ICAP1A and RAP1 proteins in integrin-mediated cell adhesion and migration.

Funding of the research unit: € 80.900

UNIVERSITY OF TORINO

Annual Grants for Local Research Projects (RILO)

TEACHING ACTIVITIES

Current teaching courses at the University of Torino, Italy

https://www.dscb.unito.it/do/docenti.pl/Show?_id=fretta#tab-didattica

http://www.medinto.unito.it/do/docenti.pl/Show?_id=fretta#profilo

- **Cell Biology** (SCB0198) - CFU: 6
(Integrated course: Cell Biology and Genetics)
University Degree Course in Medicine and Surgery (in English)
- **Applied Biology** (MED2961C) - CFU: 1
(Integrated course: Preparatory and biomedical sciences)
University Degree Course in Speech Therapy (Logopedia)
- **Applied Biology** (MED2941) - CFU: 1
(Integrated course: Preparatory and biomedical sciences)
University Degree Course in Physiotherapy (Fisioterapia)
- **Applied Biology** (MED3281C) - CFU: 1
(Integrated course: Preparatory and biomedical sciences)
University Degree Course in Orthoptics and Ophthalmological Assistance (Ortottica)
- **Applied Biology** (MED3012C) - CFU: 1
(Integrated course: Preparatory and biomedical sciences)
University Degree Course in Developmental Age Neuropsychomotricity Therapy
(Terapia della Neuropsicomotricità dell'Età Evolutiva, TNPEE)
- **Applied Biology** (SCB0036) - CFU: 1
(Integrated course: Preparatory and biomedical sciences)
University Degree Course in Psychiatric Rehabilitation Technique (Tecnica della Riabilitazione Psichiatrica, TRP)
- **Cell Biology** (INT0643) - CFU: 3
(Integrated course: Biology and Genetics)
University Master's Degree Course in Medical Biotechnology (Biotecnologie Mediche)
- **Applied Microscopy** (0188S e B8116) - CFU: 2
University First and Second Level Degree Courses in Biotechnology (Biotecnologie)
- **Cell Biology** - CFU: 1
Doctoral School in Complex Systems for Life Sciences (fino all'A.A. 2018-19)
- **ADE - Cerebrovascular malformations: pathogenetic mechanisms, diagnostic procedures and therapeutic strategies** (SCB0025) - CFU: 1
University Degree Course in Medicine and Surgery (in English)
- **ADE - Advanced microscopy techniques for biomedical applications** (SCB0024) - CFU: 1
University Degree Course in Medicine and Surgery (in English)

PROFESSIONAL UPDATING

- Participation in the Academic Teaching Excellence (ATE) course of the British Council (Milan), addressed to university teachers who teach their courses in English.
10-13 July 2017.
- Online training activities aimed at carrying out alternative teaching (E-learning, organization of online courses, creation of content, live video lessons, oral exams in telematic mode, use of the Webex, Moodle and Kaltura platforms).
March-May 2020.
- Participation in the English as a Medium of Instruction (EMI) course of the British Council (Milan), addressed to university teachers who teach their courses in English.
30 June -10 July 2020.
- Recipient and participant of the European Union (EU) Erasmus+ 2021-2027 Programme “Staff mobility for teaching and training activities”, which was carried out at the International Neuroscience Institute (INI) in Hannover (Germany) from 10 to 14 July 2023.

PUBLICATIONS ON INTERNATIONAL JOURNALS

ORCID ID: <https://orcid.org/0000-0001-9761-2959>

PubMed: <https://pubmed.ncbi.nlm.nih.gov/?term=Retta+SF&sort=date>

Scopus ID: 6603604351 - <https://www.scopus.com/authid/detail.uri?authorId=6603604351>

Web of Science ResearcherID: [Q-4770-2019](https://publons.com/researcher/2963578/saverio-francesco-retta/) - <https://publons.com/researcher/2963578/saverio-francesco-retta/>

Google Scholar: <https://scholar.google.com/citations?user=M9UZXJoAAAAJ&hl=en>

1. Kar S, Perrelli A, Bali KK, Mastrocola R, Kar A, Khan B, Gand L, Nayak A, Hartmann C, Kunz WS, Samii A, Bertalanffy H, Retta SF*. (2023). **Identification of galectin-3 as a novel potential prognostic/predictive biomarker and therapeutic target for cerebral cavernous malformation disease**. *Genes & Diseases*. 2023 Apr 3;11(1):67-71. DOI: 10.1016/j.gendis.2023.02.045. eCollection 2024 Jan. [IF: 6.9 (JCR 2023). Q1]
2. Perrelli A, Bozza A, Ferraris C, Osella S, Moglia A, Mioletti S, Battaglia L, Retta SF*. (2023). **Multidrug-Loaded Lipid Nanoemulsions for the Combinatorial Treatment of Cerebral Cavernous Malformation Disease**. *Biomedicines*. 2023 Feb 7;11(2):480. DOI: 10.3390/biomedicines11020480. [IF: 3.9 (JCR 2023). Q1]
3. Perrelli A, Ferraris C, Berni E, Glading AJ, Retta SF*. (2023). **KRIT1: A Traffic Warden at the Busy Crossroads Between Redox Signaling and the Pathogenesis of Cerebral Cavernous Malformation Disease**. *Antioxid Redox Signal*. 2023 Mar;38(7-9):496-528. DOI: 10.1089/ars.2021.0263. Epub 2022 Nov 1. [IF: 6.6 (JCR 2022). Q1]
4. Bianconi A, Salvati LF, Perrelli A, Ferraris C, Massara A, Minardi M, Aruta G, Rosso M, Massa Micon B, Garbossa D, Retta SF*. (2022). **Distant Recurrence of a Cerebral Cavernous Malformation in the Vicinity of a Developmental Venous Anomaly: Case Report of Local Oxy-Inflammatory Events**. *International Journal of Molecular Sciences*. 2022 Nov 24;23(23):14643. DOI: 10.3390/ijms232314643. [IF: 5.6 (JCR 2022). Q1]
5. Mastrocola R, Aimaretti E, Ferreira Alves G, Cento AS, Fornelli C, Dal Bello F, Ferraris C, Goitre L, Perrelli A, Retta SF*. (2022). **Heterozygous Loss of KRIT1 in Mice Affects Metabolic Functions of the Liver, Promoting Hepatic Oxidative and Glycative Stress**. *International Journal of Molecular Sciences*. 2022 Sep 22;23(19):11151. DOI: 10.3390/ijms231911151. [IF: 5.6 (JCR 2022). Q1]
6. Benedetti V, Canzoneri R, Perrelli A, Arduino C, Zonta A, Brusco A, Retta SF*. (2022). **Next-Generation Sequencing Advances the Genetic Diagnosis of Cerebral Cavernous Malformation (CCM)**. *Antioxidants (Basel)*. 2022 Jun 29;11(7):1294. DOI: 10.3390/antiox11071294. [IF: 7.0 (JCR 2022). Q1]
7. Perrelli A, Retta SF*. (2021). **Polymorphisms in genes related to oxidative stress and inflammation: Emerging links with the pathogenesis and severity of Cerebral Cavernous Malformation disease**. *Free Radical Biology and Medicine*. 2021 August 20;172:403-417. DOI: 10.1016/j.freeradbiomed.2021.06.021. [IF: 8.101 (JCR 2021). Q1]
8. Fontanella MM, Bacigaluppi S, Doglietto F, Zanin L, Agosti E, Panciani P, Belotti F, Saraceno G, Spina G, Draghi R, Fiorindi A, Cornali C, Biroli A, Kivelev J, Chiesa M, Retta SF, Gasparotti R, Kato Y, Hernesniemi J, Rigamonti D. (2021). **An international**

call for a new grading system for cerebral and cerebellar cavernomas. *Journal of Neurosurgical Sciences*. 2021 Jun;65(3):239-246. DOI: 10.23736/S0390-5616.21.05433-3. [IF: 2.392 (JCR 2021). Q3]

9. De Luca E, Perrelli A, Swamy H, Nitti M, Passalacqua M, Furfaro AL, Salzano AM, Scaloni A, Glading AJ, Retta SF*. (2021). **Protein kinase C α regulates the nucleocytoplasmic shuttling of KRIT1.** *Journal of Cell Science*. 2021 Feb 4;134(3):jcs250217. DOI: 10.1242/jcs.250217. [IF: 5.235 (JCR 2021). Q2]
10. Perrelli A, Fatehbashar zad P, Benedetti V, Ferraris C, Fontanella M, De Luca E, Moglianetti M, Battaglia L, Retta SF*. (2021). **Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM).** *Expert Opinion on Drug Delivery*. 2021 Jan 23;18(7):849-876. DOI: 10.1080/17425247.2021.1873273. [IF: 8.129 (JCR 2021). Q1]
11. Trabalzini L., Finetti F. and Retta SF*. (2020). **Cerebral Cavernous Malformations (CCM) - Methods and Protocols.** Preface. *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book).
12. Retta SF*, Perrelli A, Trabalzini L, Finetti F. (2020). **From Genes and Mechanisms to Molecular-Targeted Therapies: The Long Climb to the Cure of Cerebral Cavernous Malformation (CCM) Disease.** *Methods Mol Biol*. 2020;2152:3-25. DOI: 10.1007/978-1-0716-0640-7_1. In Trabalzini L., Finetti F. and Retta S.F. (Eds.) "Cerebral Cavernous Malformations (CCM). Methods and Protocols", *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book chapter).
13. Benedetti V, Pellegrino E, Brusco A, Piva R, Retta SF*. (2020). **Next Generation Sequencing (NGS) Strategies for Genetic Testing of Cerebral Cavernous Malformation (CCM) Disease.** *Methods Mol Biol*. 2020;2152:59-75. DOI: 10.1007/978-1-0716-0640-7_5. In Trabalzini L., Finetti F. and Retta S.F. (Eds.) "Cerebral Cavernous Malformations (CCM). Methods and Protocols", *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book chapter).
14. Delle Monache S, Retta SF. (2020). **Generation of CCM Phenotype by a Human Microvascular Endothelial Model.** *Methods Mol Biol*. 2020;2152:131-137. DOI: 10.1007/978-1-0716-0640-7_10. In Trabalzini L., Finetti F. and Retta S.F. (Eds.) "Cerebral Cavernous Malformations (CCM). Methods and Protocols", *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book chapter).
15. Goitre L, Fornelli C, Zotta A, Perrelli A, Retta SF*. (2020). **Production of KRIT1-knockout and KRIT1-knockin Mouse Embryonic Fibroblasts as Cellular Models of CCM Disease.** *Methods Mol Biol*. 2020;2152:151-167. DOI: 10.1007/978-1-0716-0640-7_12. In Trabalzini L., Finetti F. and Retta S.F. (Eds.) "Cerebral Cavernous Malformations (CCM). Methods and Protocols", *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book chapter).

16. Delle Monache S, Retta SF. (2020). **Study of CCM Microvascular Endothelial Phenotype by an In Vitro Tubule Differentiation Model**. *Methods Mol Biol.* 2020;2152:371-375. DOI: 10.1007/978-1-0716-0640-7_26. In Trabalzini L., Finetti F. and Retta S.F. (Eds.) "Cerebral Cavernous Malformations (CCM). Methods and Protocols", *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book chapter).
17. Marchi S, Retta SF, Pinton P. (2020). **Detection of p62/SQSTM1 Aggregates in Cellular Models of CCM Disease by Immunofluorescence**. *Methods Mol Biol.* 2020;2152:417-426. DOI: 10.1007/978-1-0716-0640-7_30. In Trabalzini L., Finetti F. and Retta S.F. (Eds.) "Cerebral Cavernous Malformations (CCM). Methods and Protocols", *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book chapter).
18. Antognelli C, Talesa VN, Retta SF. (2020). **Spectrophotometric Method for Determining Glyoxalase 1 Activity in Cerebral Cavernous Malformation (CCM) Disease**. *Methods Mol Biol.* 2020;2152:445-449. DOI: 10.1007/978-1-0716-0640-7_33. In Trabalzini L., Finetti F. and Retta S.F. (Eds.) "Cerebral Cavernous Malformations (CCM). Methods and Protocols", *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book chapter).
19. Perrelli A and Retta SF*. (2020). **Fluorescence Analysis of Reactive Oxygen Species (ROS) in Cellular Models of Cerebral Cavernous Malformation Disease**. *Methods Mol Biol.* 2020;2152:451-465. DOI: 10.1007/978-1-0716-0640-7_34. In Trabalzini L., Finetti F. and Retta S.F. (Eds.) "Cerebral Cavernous Malformations (CCM). Methods and Protocols", *Methods in Molecular Biology* vol. 2152, pp. 398. Springer Nature (Basel, CH). ISBN: 978-1-07-160640-7; DOI: 10.1007/978-1-0716-0640-7. (Book chapter).
20. Kim AH, Perrelli A, Ragni A, Retta F, De Silva TM, Sobey GC, Retta SF*. (2020). **Vitamin D Deficiency and the Risk of Cerebrovascular Disease**. *Antioxidants (Basel)*. 2020 Apr 17; 9(4), pii: E327; doi:10.3390/antiox9040327. [IF: 6.312 (JCR 2020). Q1]
21. Antognelli C, Perrelli A, Armeni T, Nicola Talesa V, Retta SF*. (2020). **Dicarbonyl Stress and S-Glutathionylation in Cerebrovascular Diseases: A Focus on Cerebral Cavernous Malformations**. *Antioxidants (Basel)*. 2020 Feb 1; 9(2). pii: E124. doi: 10.3390/antiox9020124. [IF: 6.312 (JCR 2020). Q1]
22. Moglianetti M, Pedone D, Udayan G, Retta SF, Debellis D, Marotta R, Turco A, Rella S, Malitesta C, Bonacucina G, De Luca E, Pompa PP. (2020). **Intracellular Antioxidant Activity of Biocompatible Citrate-Capped Palladium Nanozymes**. *Nanomaterials*. 2020 Jan 3;10(1). pii: E99. doi: 10.3390/nano10010099. [IF: 5.076 (JCR 2020). Q1]
23. Finetti F, Schiavo I, Ercoli J, Zotta A, Boda E, Retta SF, Trabalzini L. (2020). **KRIT1 loss-mediated upregulation of NOX1 in stromal cells promotes paracrine pro-angiogenic responses**. *Cellular Signalling*. 2020 Apr; 68:109527. doi: 10.1016/j.cellsig.2020.109527. [IF: 4.315 (JCR 2020). Q2]

24. Vieceli Dalla Sega F, Mastrocola R, Aquila G, Fortini F, Fornelli C, Zotta A, Cento AS, Perrelli A, Boda E, Pannuti A, Marchi S, Pinton P, Ferrari R, Rizzo P, Retta SF*. (2019). **KRIT1 Deficiency Promotes Aortic Endothelial Dysfunction**. *International Journal of Molecular Sciences*. 2019 Oct 5; pii: E4930. doi:c10.3390/ijms20194930. [IF: 4.556 (JCR 2019). Q1]
25. Cianfruglia L, Perrelli A, Fornelli C, Magini A, Gorbi S, Salzano AM, Antognelli C, Retta F, Benedetti V, Cassoni P, Emiliani C, Principato G, Scaloni A, Armeni T, Retta SF*. (2019). **KRIT1 Loss-Of-Function Associated with Cerebral Cavernous Malformation Disease Leads to Enhanced S-Glutathionylation of Distinct Structural and Regulatory Proteins**. *Antioxidants (Basel)*. 2019 Jan 17;8(1):1-28. [IF: 5.014 (JCR 2019). Q1]
26. De Luca E, Pedone D, Moglianetti M, Pulcini D, Perrelli A, Retta SF* & Pompa PP (2018). **Multifunctional Platinum@BSA-Rapamycin Nanocarriers for the Combinatorial Therapy of Cerebral Cavernous Malformation**. *ACS Omega*, 2018 Nov 30;3(11):15389-15398. [IF: 2.584 (JCR 2018). Q1]
27. Perrelli A, Goitre L, Salzano AM, Moglia A, Scaloni A, and Retta SF*. (2018). **Biological Activities, Health Benefits, and Therapeutic Properties of Avenanthramides: From Skin Protection to Prevention and Treatment of Cerebrovascular Diseases**. *Oxidative Medicine and Cellular Longevity* 2018, 6015351. [IF: 4.868 (JCR 2018). Q2]
28. Finetti F, Moglia A, Schiavo I, Donnini S, Berta GN, Di Scipio F, Perrelli A, Fornelli C, Trabalzini L, and Retta SF*. (2018). **Yeast-Derived Recombinant Avenanthramides Inhibit Proliferation, Migration and Epithelial Mesenchymal Transition of Colon Cancer Cells**. *Nutrients* 2018, 10(9), 1159. [IF: 4.171 (JCR 2018). Q1]
29. Antognelli C, Trapani E, Delle Monache S, Perrelli A, Daga M, Pizzimenti S, Barrera G, Cassoni P, Angelucci A, Trabalzini L, Talesa VN, Goitre L, Retta SF*. (2018). **KRIT1 loss-of-function induces a chronic Nrf2-mediated adaptive homeostasis that sensitizes cells to oxidative stress: Implication for Cerebral Cavernous Malformation disease**. *Free Radical Biology and Medicine* 2018 Feb 1; 115:202-218. Epub 2017 Nov 21. [IF: 6.020 (JCR 2017). Q1].
30. Antognelli C, Trapani E, Delle Monache S, Perrelli A, Fornelli C, Retta F, Cassoni P, Talesa VN, Retta SF*. (2017). **Data in support of sustained upregulation of adaptive redox homeostasis mechanisms caused by KRIT1 loss-of-function**. *Data Brief*. 2017 Dec 13; 16:929-938. [Rank by JCR/JCI 2018: Q2]
31. Goitre L, DiStefano PV, Moglia A, Nobiletti N, Baldini E, Trabalzini L, Keubel J, Trapani E, Shuvaev VV, Muzykantov VR, Sarelius IH, Retta SF* & Glading AJ. (2017). **Up-regulation of NADPH oxidase-mediated redox signaling contributes to the loss of barrier function in KRIT1 deficient endothelium**. *Scientific Reports*, 2017 Aug 15; 7(1):8296. [IF: 4.122 (JCR 2017). Q1]
32. Retta SF* and Glading AJ. (2016). **Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin**. *International Journal of Biochemistry & Cell Biology*. 2016 Dec; 81(Pt B):254-270. [IF: 3.505 (JCR 2016). Q2]

33. Marchi S, Trapani E, Corricelli M, Goitre L, Pinton P, Retta SF*. (2016). **Beyond Multiple Mechanisms and a Unique Drug: Defective Autophagy as Pivotal Player in Cerebral Cavernous Malformation Pathogenesis and Implications for Targeted Therapies.** *Rare Diseases*, 2016 Jan 25; 4:1, e1142640.
34. Marchi S, Retta SF*, Pinton P. (2016). **Cellular processes underlying cerebral cavernous malformations: Autophagy as another point of view.** *Autophagy*, 2016 Feb; 12(2):424-5. [IF: 8.593 (JCR 2016). Q1]
35. Moglianetti M, De Luca E, Pedone D, Marotta R, Catelani T, Sartori B, Amenitsch H, Retta SF, Pompa PP. (2016). **Platinum nanozymes recover cellular ROS homeostasis in oxidative stress-mediated disease model.** *Nanoscale*, 2016 Feb 14; 8(6):3739-52. [IF: 7.367 (JCR 2016). Q1]
36. Choquet H, Trapani E, Goitre L, Trabalzini L, Akers A., Fontanella M, Hart BL, Morrison LA, Pawlikowska L, Kim H, Retta SF*. (2016). **Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.** *Free Radical Biology and Medicine*, 2016 Jan 19; 92:100-109. [IF: 5.606 (JCR 2016). Q1]
37. Marchi S, Corricelli M, Trapani E, Bravi L, Pittaro A, Delle Monache S, Ferroni L, Patergnani S, Missiroli S, Goitre L, Trabalzini L, Rimessi A, Giorgi C, Zavan B, Cassoni P, Dejana E, Retta SF*, Pinton P. (2015). **Defective autophagy is a key feature of cerebral cavernous malformations.** *EMBO Molecular Medicine*, 2015. 7(11):1403-1417. [IF: 9.547 (JCR 2015). Q1]
38. Trapani E, Retta SF*. (2015). **Cerebral cavernous malformation (CCM) disease: from monogenic forms to genetic susceptibility factors.** *Journal of Neurosurgical Sciences*, 2015 Sep; 59(3):201-9. [IF: 1.651 (JCR 2015). Q2]
39. Keller B, Mühlenkamp M, Deuschle E, Siegfried A, Mössner S, Schade J, Griesinger T, Katava N, Braunsdorf C, Fehrenbacher B, Jiménez-Soto LF, Schaller M, Haas R, Genth H, Retta SF, Meyer H, Böttcher RT, Zent R, Schütz M, Autenrieth IB, Bohn E. (2015). **Yersinia enterocolitica exploits different pathways to accomplish adhesion and toxin injection into host cells.** *Cellular Microbiology*, 2015 Aug; 17(8):1179-1204. [IF: 4.460 (JCR 2015). Q1]
40. Moglia A., Goitre L., Gianoglio S., Baldini E., Trapani E., Genre A., Scattina A., Dondo G., Trabalzini L., Beekwilder J., Retta S.F.* (2015) **Evaluation of the bioactive properties of avenanthramide analogues produced in recombinant yeast.** *BioFactors*, 2015, 41(1):15-27. [IF: 4.504 (JCR 2015). Q1]
41. Gibson C., Zhu W., Davis C.T., Bowman-Kirigin J.A., Chan A.C., Ling J., Walker A.E., Goitre L., Delle Monache S., Retta S.F., Shiu Y-T E., Grossmann A.H., Thomas K.R., Donato A.J., Lesniewski L.A., Whitehead K.J., Li D.J. (2015) **Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation.** *Circulation*, 2015; 131(3):289-99. [IF: 17.202 (JCR 2015). Q1]
42. Fontanella MM, Panciani PP, Spina G, Roca E, Migliorati K, Ambrosi C, Sturiale CL, Retta SF (2015) **Professional athletes and cerebral cavernomas: an obstacle to**

overcome. *Journal of Sports Medicine and Physical Fitness*, 2015 Sep; 55(9):1046-7. [IF: 1.111 (JCR 2015). Q3]

43. Goitre L, De Luca E, Braggion S, Trapani E, Guglielmotto M, Biasi F, Forni M, Moglia A, Trabalzini L, Retta SF*. (2014) **KRIT1 loss of function causes a ROS-dependent upregulation of c-Jun.** *Free Radical Biology and Medicine*, 2014 Mar; 68:134-47. [IF: 5.736 (JCR 2014). Q1]
44. Trabalzini L. and Retta SF (2014) **Ras Signaling - Methods and Protocols.** Preface. *Methods in Molecular Biology* (Clifton, N.J.), v. 1120; Springer protocols (Series). Humana Press Inc. (USA). ISBN-10: 162703790X; ISBN-13: 978-1627037907. (Book).
45. Goitre L, Trapani E, Trabalzini L, Retta SF*. (2014) **The ras superfamily of small GTPases: the unlocked secrets.** *Methods Mol Biol.* 2014; 1120:1-18. In Trabalzini L. and Retta S.F. (Eds.) "Ras Signaling - Methods and Protocols", *Methods in Molecular Biology* vol. 1120, pp. 425. Humana Press Inc. (USA). ISBN-10: 162703790X; ISBN-13: 978-1627037907. (Book chapter).
46. Ferro E, Goitre L, Baldini E, Retta SF, Trabalzini L. (2014) **Ras GTPases are both regulators and effectors of redox agents.** *Methods Mol Biol.* 2014; 1120:55-74. In Trabalzini L. and Retta S.F. (Eds.) "Ras Signaling - Methods and Protocols", *Methods in Molecular Biology* vol. 1120, pp. 425. Humana Press Inc. (USA). ISBN-10: 162703790X; ISBN-13: 978-1627037907. (Book chapter).
47. Goitre L, Retta SF* (2014) **Combined pulldown and time-lapse microscopy studies for determining the role of Rap1 in the crosstalk between integrins and cadherins.** *Methods Mol Biol.* 2014; 1120:177-95. In Trabalzini L. and Retta S.F. (Eds.) "Ras Signaling - Methods and Protocols", *Methods in Molecular Biology* vol. 1120, pp. 425. Humana Press Inc. (USA). ISBN-10: 162703790X; ISBN-13: 978-1627037907. (Book chapter).
48. Goitre L, Cutano V, Retta SF* (2014) **Fluorescence microscopy study of Rap1 subcellular localization.** *Methods Mol Biol.* 2014; 1120:197-205. In Trabalzini L. and Retta SF. "Ras Signaling - Methods and Protocols", *Methods in Molecular Biology* vol. 1120, pp. 425. Humana Press Inc. (USA). ISBN-10: 162703790X; ISBN-13: 978-1627037907. (Book chapter).
49. Maddaluno L, Rudini N, Cuttano R, Bravi L, Giampietro C, Corada M, Ferrarini L, Orsenigo F, Papa E, Boulday G, Tournier-Lasserre E, Chapon F, Richichi C, Retta SF, Lampugnani MG, Dejana E. (2013) **EndMT contributes to the onset and progression of cerebral cavernous malformations.** *Nature*, 2013; 498(7455):492-6. [IF: 42.351 (JCR 2013). Q1]
50. Orso F, Balzac F, Marino M, Lembo A, Retta SF, Taverna D. (2013) **miR-21 coordinates tumor growth and modulates KRIT1 levels.** *Biochemical and Biophysical Research Communications* 2013; 438(1):90-6. [IF: 2.281 (JCR 2013). Q3]
51. Di Gregorio E, Bianchi FT, Schiavi A, Chiotto AM, Rolando M, Verdun di Cantogno L, Grosso E, Cavalieri S, Calcia A, Lacerenza D, Zuffardi O, Retta SF, Stevanin G, Marelli C, Durr A, Forlani S, Chelly J, Montarolo F, Tempia F, Beggs HE, Reed R, Squadrone S, Abete MC, Brussino A, Ventura N, Di Cunto F, Brusco A. (2013) **A de**

novo X;8 translocation creates a PTK2-THOC2 gene fusion with THOC2 expression knockdown in a patient with psychomotor retardation and congenital cerebellar hypoplasia. *Journal of Medical Genetics*, 2013; 50(8):543-51. [IF: 5.636 (JCR 2013). Q1]

52. Bacigaluppi S, Retta S.F., Pileggi S, Fontanella M, Goitre L, Tassi L, La Camera A, Citterio A, Patrosso MC, Tredici G, Penco S. (2013) **Genetic and cellular basis of Cerebral Cavernous Malformations: implications for clinical management.** *Clinical Genetics*, 2013; 83(1):7-14. [IF: 3.652 (JCR 2013). Q2]
53. Guazzi P, Goitre L, Ferro E, Cutano V, Martino C, Trabalzini L, Retta S.F.* (2012) **Identification of the Kelch family protein Nd1-L as a novel molecular interactor of KRIT1.** *PLoS One*, 2012; 7(9):e44705. [IF: 3.730 (JCR 2012). Q1]
54. Retta S.F.*, Chiarugi P, Trabalzini L, Pinton P, Belkin AM. (2012) **Reactive oxygen species: friends and foes of signal transduction.** *Journal of Signal Transduction*, 2012:534029. [Epub 2012 Mar 11]. [Special Issue].
55. Goitre L., Pergolizzi B., Ferro E., Trabalzini L., Retta S.F.* (2012) **Molecular Crosstalk between Integrins and Cadherins: do Reactive Oxygen Species Set the Talk?** *Journal of Signal Transduction*, 2012:807682. [Epub 2011 Dec 13].
56. Ferro E., Goitre L., Retta S.F., Trabalzini L. (2012) **The interplay between ROS and Ras GTPases: physiological and pathological implications.** *Journal of Signal Transduction*, 2012:365769. [Epub 2011 Nov 30].
57. D'Angelo R., Marini V., Rinaldi C., Origone P., Dorcaratto A., Avolio M., Goitre L., Forni M., Capra V., Alataci C., Marenzi C., Garrè C., Bramanti P., Sidoti A., Retta S.F.*, Amato A. (2011). **Mutation Analysis of CCM1, CCM2 and CCM3 Genes in a Cohort of Italian Patients with Cerebral Cavernous Malformation.** *Brain Pathology*, 2011; 21(2): 215–224. [IF: 3.995 (JCR 2011). Q1]
58. Goitre L., Balzac F., Degani S., Degan P., Marchi S., Pinton P., Retta S.F.* (2010). **KRIT1 Regulates the Homeostasis of Intracellular Reactive Oxygen Species.** *PLoS One*, 2010; 5(7):e11786. [IF: 4.411 (JCR 2010). Q1]
59. Li L, Wang S, Jezierski A, Moalim-Nour L, Mohib K, Parks RJ, Retta S.F., Wang L. (2010). **A unique interplay between Rap1 and E-cadherin in the endocytic pathway regulates self-renewal of human embryonic stem cells.** *Stem Cells*, 2010; 28 (2): 247-257. [IF: 7.871 (JCR 2010). Q1]
60. Moglia A, Comino C, Lanteri S, de Vos R, de Waard P, van Beek TA, Goitre L, Retta S.F., Beekwilder J. (2010). **Production of novel antioxidative phenolic amides through heterologous expression of the plant's chlorogenic acid biosynthesis genes in yeast.** *Metabolic Engineering*, 2010; 12:223-232. [IF: 5.512 (JCR 2010). Q1]
61. Jimenez-Soto LF, Kutter S, Sewald X, Ertl C, Weiss E, Kapp U, Rohde M, Pirch T, Jung K, Retta S.F., Terrado L, Fischer W, Haas R. (2009) **Helicobacter pylori Type IV Secretion Apparatus Exploits β 1 Integrin in a Novel RGD-Independent Manner.** *PLoS Pathogens*, 2009; 5(12): e1000684. [IF: 8.978 (JCR 2009). Q1]

62. Francalanci F., Avolio M., De Luca E., Longo D., Menchise V., Guazzi P., Sgrò F., Marino M., Goitre L., Balzac F., Trabalzini L., Retta S.F.* (2009). **Structural and functional differences between KRIT1A and KRIT1B isoforms: a framework for understanding CCM pathogenesis.** *Experimental Cell Research*, 2009; 315:285-303. [IF: 3.589 (JCR 2009). Q2]
63. Vanni C., Visco V., Parodi A., Ottaviano C., Manazza A., Retta S.F., Varesio L., Mancini P., Torrisi M.R., Eva A. (2006). **Inhibition of PI3K induces Rac activation and membrane ruffling in protoDbl expressing cells.** *Cell Cycle*, 2006; 5:2657-2665. [IF: 3.214 (JCR 2006). Q2]
64. Retta S.F.*, Balzac F., Avolio M. (2006). **Rap1: a turnabout for the crosstalk between cadherins and integrins.** *European Journal of Cell Biology*, 2006; 85:283-293. [IF: 3.039 (JCR 2006). Q2]
65. Balzac F, Avolio M, Degani S, Kaverina I, Torti M, Silengo L, Small JV, Retta SF*. (2005). **E-cadherin endocytosis regulates the activity of Rap1: a traffic light GTPase at the crossroads between cadherin and integrin function.** *Journal of Cell Science*, 2005; 118(20):4765-4783. [IF: 6.543 (JCR 2005). Q1]
66. Fournier HN, Dupé-Manet S, Bouvard D, Luton F, Degani S, Block MR, Retta S.F., Albiges-Rizo C. (2005). **Nuclear translocation of ICAP-1 stimulates cellular proliferation.** *Molecular Biology of the Cell*, 2005; 16:1859-1871. [IF: 6.520 (JCR 2005). Q1]
67. Retta S.F.*, Avolio M., Francalanci F., Procida S., Balzac F., Degani S., Tarone G., Silengo L. (2004). **Identification of Krit1B: a Novel Alternative Splicing Isoform of Cerebral Cavernous Malformation Gene-1 (CCM1).** *Gene*, 2004; 325:63-78. [IF: 2.705 (JCR 2004). Q2]
68. Arcucci A, Alaia V, Montagnani S, Pontarelli G, Retta S.F., Tarone G, Gionti E (2003) **Altered expression of integrins in RSV-transformed chick epiphyseal chondrocytes.** *Biochimie*, 2003; 85(5):483-92. [IF: 3.707 (JCR 2003). Q1]
69. Bouvard D, Vignoud L, Dupe-Manet S, Abed N, Fournier HN, Vincent-Monegat C, Retta SF, Fassler R, Block MR (2003). **Disruption of focal adhesions by integrin cytoplasmic domain-associated protein-1 alpha.** *Journal of Biological Chemistry*, 2003; 278:6567-6574. [IF: 6.482 (JCR 2003). Q1]
70. Degani S, Balzac F, Brancaccio M, Guazzone S, Retta SF, Silengo L, Eva A, Tarone G. (2002). **The integrin cytoplasmic domain-associated protein ICAP-1 binds and regulates Rho family GTPases during cell spreading.** *Journal of Cell Biology*, 2002; 156: 377-387. [IF: 12.522 (JCR 2002). Q1]
71. Moro L, Dolce L, Cabodi S, Bergatto E, Erba EB, Smeriglio M, Turco E, Retta SF, Giuffrida MG, Venturino M, Godovac-Zimmermann J, Conti A, Schaefer E, Beguinot L, Tacchetti C, Gaggini P, Silengo L, Tarone G, Defilippi P. (2002). **Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines.** *Journal of Biological Chemistry*, 2002; 277:9405-9414. [IF: 6.696 (JCR 2002). Q1]

72. Retta S.F.*, Cassarà G., D'Amato M., Alessandro R., Pellegrino M., Degani S., De Leo G., Silengo L., Tarone G. (2001). **Cross Talk between β 1 and β 3 Integrins: β 1 Affects β 3 mRNA Stability**. *Molecular Biology of the Cell*, 2001; 12:3126-3138. [IF: 7.700 (JCR 2001). Q1]
73. Tarone G, Hirsch E, Brancaccio M, De Acetis M, Barberis L, Balzac F, Retta SF, Botta C, Altruda F, Silengo L. (2000). **Integrin function and regulation in development**. *International Journal of Developmental Biology*, 2000; 44(6):725-31. [IF: 1.963 (JCR 2000). Q2]
74. Cali G., Mazzarella C., Chiacchio M., Negri R., Retta S.F., Zannini M., Gentile F., Tarone G., Nitsch L., Garbi C. (1999). **RhoA activity is required for fibronectin assembly and counteracts β 1B integrin inhibitory effect in FRT epithelial cells**. *Journal of Cell Science*, 1999; 112:957-965. [IF: 6.044 (JCR 1999). Q1]
75. Tomatis D., Echtermayer F., Schober S., Balzac F., Retta S.F., Silengo L., Tarone G. (1999). **The muscle-specific laminin receptor alpha7beta1 integrin negatively regulates alpha5beta1 fibronectin receptor function**. *Experimental Cell Research*, 1999; 246:421-432. [IF: 3.256 (JCR 1999). Q2]
76. Retta S.F.*, Ferraris P., Tarone G. (1999). **Purification of Fibronectin from Human Plasma**. *Methods Mol Biol*. 1999; 96:119-124. In Dejana E. and Corada M. "Adhesion Protein Protocols", *Methods in Molecular Biology* vol. 96, pp. 229. Humana Press Inc. (USA). (Book chapter).
77. Retta S.F.*, Ternullo M., Tarone G. (1999). **Adhesion to Matrix Proteins**. *Methods Mol Biol*. 1999; 96:125-130. In Dejana E. and Corada M. "Adhesion Protein Protocols", *Methods in Molecular Biology* vol. 96, pp. 229. Humana Press Inc. (USA). (Book chapter).
78. Retta S.F.*, Balzac F., Ferraris, P., Belkin, A.M., Fässler R., Humphries M., De Leo G., Silengo L., Tarone G. (1998). **β 1 Integrin Cytoplasmic Subdomains Involved in Dominant Negative Function**. *Molecular Biology of the Cell*, 1998; 9: 715-731. [IF: 7.527 (JCR 1999). Q1]
79. Belkin A.M. and Retta S.F. (1998). **β 1D Integrin Inhibits Cell Cycle Progression in Normal Myoblasts and Fibroblasts**. *Journal of Biological Chemistry*, 1998; 273: 15234-15240. [IF: 7.666 (JCR 1999). Q1]
80. Cali G., Retta S.F., Negri R., Damiano I., Gentile R., Tarone G., Nitsch L., Garbi C. (1998). **β 1B Integrin Interferes With Matrix Assembly but not with Confluent Monolayer Polarity, and Alters Some Morphogenetic Properties of FRT epithelial Cells**. *European Journal of Cell Biology*, 1998; 65:107-117. [IF: 3.043 (JCR 1999). Q2]
81. Belkin A.M., Retta S.F., Pletjushkina O.Y., Balzac F., Silengo L., Koteliansky V.E., Burrige K., Tarone G. (1997). **Muscle β 1D Integrin Reinforces The Cytoskeletal-Matrix Link: Modulation of Integrin Adhesive Function by Alternative Splicing**. *Journal of Cell Biology*, 1997; 139:1583-1595. [IF: 12.880 (JCR 1999). Q1]
82. Retta S.F.*, Barry S.T., Critchley D.R., Defilippi P., Silengo L., Tarone G. (1996). **Focal Adhesion and Stress Fibre Formation is Regulated by Tyrosine**

Phosphatase Activity. *Experimental Cell Research*, 1996; 229: 307-317. [IF: 3.256 (JCR 1999). Q2]

83. Defilippi P., Retta S.F., Olivo C., Palmieri M., Venturino M., Silengo L., Tarone G.. (1995). **p125FAK Tyrosine Phosphorylation and Focal Adhesion Assembly: Studies with Phosphotyrosine Phosphatase Inhibitors.** *Experimental Cell Research*, 1995; 221:141-152. [IF: 3.256 (JCR 1999). Q2]
84. Defilippi P., Balzac F., Retta S.F., Bozzo C., Melchiorri A., Geuna M., Silengo L., Tarone G. (1995). **Role of β 1 integrin cytoplasmic domain in signalling and cell adhesion.** In Papa S. and Tager J.M. "*Biochemistry of Cell Membranes: A Compendium of Selected Topics*". (pp. 273-290). Birkhauser Verlag AG (Basel, Switzerland). ISBN-10: 3764350563; ISBN-13: 978-3764350567. (Book chapter).
85. Balzac F., Retta S.F., Albin A., Melchiorri A., Koteliansky V.E., Geuna M., Silengo L., Tarone G. (1994). **Expression of β 1B Integrin Isoform in CHO Cells Results in a Dominant Negative Effect on Cell Adhesion and Motility.** *Journal of Cell Biology*, 1994; 127: 557-565. [IF: 12.880 (JCR 1999). Q1]
86. Retta S.F., Sidari M., Nardi S., Cacco G. (1994). **Effect of the low molecular size (LMS) humic fraction on differentiation processes in leaf explants.** In Senesi N. and Miano T.M. "*Humic substances in the global environment and implications on human health*". (pp. 349-354). Elsevier Science B.V. (Amsterdam). ISBN-10: 0-444-89593-0; ISBN-13: 978-0-444-89593-6. (Book chapter).

* Corresponding author

Total articles:	86
Journal articles:	68
• Q1 articles (ISI-JCR):	44
• Q2 articles (ISI-JCR):	17
• Q3 articles (ISI-JCR):	7
Book chapters:	16
Book prefaces:	2
Books:	2
First/last/joint last author:	56

SCIENTIFIC PRODUCTION INDICATORS

№ of articles in the last 10 years (2014-2023), cited in PubMed: 46

№ of articles in the last 10 years (2014-2023), cited in Scopus: 46

№ of citations in the last 15 years (2009-2023) (*Scopus data*): 2966

15-year *h*-index (2009-2023) (*Scopus data*): 28

Total number of articles (1994-2024): 86

Total number of articles cited in PubMed (1994-2024): 82

Total number of articles cited in Scopus (1994-2024): 80

Total citations (1994-2024) (*Scopus data*): 3879

Total *h*-index (1994-2024) (*Scopus data*): 36